Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven SARS-CoV-2 infection by an accepted assay with symptoms consistent with COVID-19~* Ability to measure and quantify viral load by quantitative PCR~* Age 18 to 89~* Ability to swallow oral medications~* Patients must read, understand and sign IRB approved informed consent~Exclusion Criteria:~* Pregnancy or women who are breast feeding~* Two consecutive negative assays for SARS-CoV-2 infection~* Patients that lack decision-making capacity will not be approached to participate in this study~* Inability to tolerate oral medications~* Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate~* QTc interval \> 470 mSEC~* History of ongoing ventricular cardiac dysrhythmias of grade 2 as described by NCI CTCAE 5.0 criteria~* History of serious ventricular arrhythmia (VT or VF \> 3 beats in a row)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Hydroxychloroquine Sulfate + Azithromycin (Type: EXPERIMENTAL): * Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days~* Azithromycin 500 mg taken by mouth on Day 1, followed by~* Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days.
- Arm 2: Hydroxychloroquine Sulfate alone (Type: EXPERIMENTAL): • Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
- Arm 3: Placebo (Type: NO_INTERVENTION): * Placebo pills Days 1-6.~* If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).